Unknown

Dataset Information

0

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

ABSTRACT:

SUBMITTER: Skilton M 

PROVIDER: S-EPMC6353056 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
| S-EPMC6513216 | biostudies-literature
Unknown Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
| S-EPMC6464785 | biostudies-literature
Unknown Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
| S-EPMC8094390 | biostudies-literature
Unknown TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
| S-EPMC7159432 | biostudies-literature
Unknown Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
| S-EPMC8658147 | biostudies-literature
Unknown New and emerging targeted therapies for cystic fibrosis.
| S-EPMC4817245 | biostudies-literature
Unknown Antibiotic and anti-inflammatory therapies for cystic fibrosis.
| S-EPMC3784810 | biostudies-literature
Unknown Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
| S-EPMC6322038 | biostudies-literature
Unknown Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
| S-EPMC4159205 | biostudies-other
Unknown Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.
| S-EPMC6685978 | biostudies-literature